December 19, 2008 -- China Biologic Products, Inc. announced a number of changes to the agreement under which it will acquire a 90% controlling interest in Chongqing Dalin Biologic Technologies Co., Ltd. Dalin currently owns a 54% stake in Qianfeng Biological Products Co., Ltd. Like China Biologic, Qianfeng is a plasma-based biopharmaceutical company. While performing its due diligence, China Biologic found that Dalin owns only a 43.3% interest in Qianfeng instead of the 54% China Biologic originally bargained for. More details...
